Gyre Therapeutics

Anti-fibrotic/anti-inflammatory drugs, commercialized via majority-owned China subsidiary (Beijing Continent Pharmaceutical / Gyre Pharmaceuticals)

GYRE · Nasdaq · United States

Share price · GYRE

$4.34-2.64 (-37.82%) 3M

close as of 2026-11-18 · 24h delayed · vol 467K (2.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GYRE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+18.7%
  2. 30 Oct 2026-28.9%

    Nothing announced by GYRE that day or the session before.

  3. 29 Oct 2026-9.6%
  4. 28 Oct 2026+8.6%
  5. 18 Sep 2026+5.2%

    Nothing announced by GYRE that day or the session before.

  6. 4 Sep 2026+6.5%
  7. 17 Jul 2026-5.8%
  8. 2 Jul 2026+12.6%

    Nothing announced by GYRE that day or the session before.

  9. 4 Jun 2026+8.8%

    Nothing announced by GYRE that day or the session before.

  10. 7 May 2026-12.1%

Share of unusual movement by asset

For each asset, the share of GYRE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—28%
Sessions with no dated event—72%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Preclinical / Unstaged
Endothelin A receptorSmall molecule
Pulmonary Arterial Hypertension

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 May 2026Filing acceptedHydronidoneNMPA accepts NDA for F351 (hydronidone)
CN, NMPA · Source ↗
March 2026Priority reviewHydronidoneNMPA grants priority review to F351
CN, NMPA · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$33M—$42M+ $16M short-term inv.$2.5M-$4.0M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$29M—$43M+ $14M short-term inv.$14M-$17M operating cash flowreport ↗
2026-Q1$23M$6.7M$38M+ $12M short-term inv.$9.9M$3.2M operating cash flowreport ↗
2025-Q3$31M$2.4M$40M+ $20M short-term inv.—$4.7M operating cash flowreport ↗
2025-Q2$27M$3.4M$36M+ $18M short-term inv.—$2.1M operating cash flowreport ↗
2025-Q1$22M$3.1M$15M+ $15M short-term inv.—-$0.1M operating cash flowreport ↗
2024-Q3$25M$2.8M$16M+ $9.2M short-term inv.—$1.7M operating cash flowreport ↗
2024-Q2$25M$3.4M$16M+ $9.0M short-term inv.—-$5.5M operating cash flowreport ↗
2024-Q1$27M$2.2M$30M+ $7.6M short-term inv.—$2.9M operating cash flowreport ↗
2023-Q3$32M$0.4M$2.2M$1.6M-$3.2M operating cash flowreport ↗
2023-Q2$29M$0.3M$6.9M$2.5M-$2.5M operating cash flowreport ↗
2023-Q1$25M$0.6M$8.1M—-$6.2M operating cash flowreport ↗
2022-Q3—$0.8M$23M+ $0 short-term inv.$4.9M-$7.3M operating cash flowreport ↗
2022-Q2—$1.9M$75M+ $0 short-term inv.—-$12M operating cash flowreport ↗
2022-Q1$0.8M$9.7M$35M+ $0 short-term inv.$15M-$12M operating cash flowreport ↗
2021-Q3$2.3M$20M$59M+ $5.4M short-term inv.$25M-$22M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$117M$14M$37M+ $15M short-term inv.—$1.0M operating cash flowreport ↗

Gyre Therapeutics reported full-year 2025 revenue of $116.6M, up 10.2% YoY, with R&D spend of $13.7M, up 14.0% YoY. Cash and cash equivalents totaled $37.07M at year-end, while cash, cash equivalents, and short-term and long-term bank deposits were $75.9M. The company reported full-year net income of $9.9M.

Management issued 2026 revenue guidance of $100.5M to $111.0M, representing a YoY decline of approximately 13.8% to 4.8%. Gyre also announced an agreement to acquire Cullgen in an all-stock transaction valued at approximately $300M, expected to close in Q2 2026, reported alignment with China’s CDE on a conditional approval filing for Hydronidone with NDA submission expected in the first half of 2026, completed enrollment in the 52-week Phase 3 pirfenidone pneumoconiosis trial with 272 patients across 18 sites, and anticipates a U.S. IND for Hydronidone in MASH-associated liver fibrosis in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$106M$12M$12M+ $15M short-term inv.—-$3.6M operating cash flowreport ↗
2023-FY$113M$14M$34M$21M$26M operating cash flowreport ↗
2022-FY$102M—$22M+ $0 short-term inv.$2.1M-$33M operating cash flowreport ↗
2021-FY$7.3M$69M$44M+ $2.5M short-term inv.$22M-$84M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 18 sales ($953K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-03Kirkby Maxwell · directorAward / grant (derivative)40,000——Form 4
2026-08-03Weston Claire · directorAward / grant (derivative)40,000——Form 4
2026-06-18Ye Weiguo · Chief Operating OfficerOption exercise3,000$0.75$2KForm 4
2026-06-18Ye Weiguo · Chief Operating OfficerOpen-market sale3,000$6.35$19KForm 4
2026-06-18Ye Weiguo · Chief Operating OfficerOption exercise (derivative)3,000——Form 4
2026-06-11Ye Weiguo · Chief Operating OfficerOption exercise2,800$0.75$2KForm 4
2026-06-11Ye Weiguo · Chief Operating OfficerOpen-market sale2,800$6.17$17KForm 4
2026-06-11Ye Weiguo · Chief Operating OfficerOption exercise (derivative)2,800——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 56 reporting institutions held 3.4M shares ($23.7M, 3.0% of shares outstanding).

#InstitutionSharesValue
1VANGUARD CAPITAL MANAGEMENT LLC984,204$6.9M
2BlackRock, Inc.758,630$5.3M
3GEODE CAPITAL MANAGEMENT, LLC431,414$3.0M
4STATE STREET CORP216,326$1.5M
5SBI Securities Co., Ltd.170,837$1.2M
6CHARLES SCHWAB INVESTMENT MANAGEMENT INC165,238$1.2M
7VANGUARD FIDUCIARY TRUST CO137,682$960K
8NORTHERN TRUST CORP133,841$933K
9GOLDMAN SACHS GROUP INC73,122$510K
10VANGUARD PORTFOLIO MANAGEMENT LLC69,814$487K
11Bank of New York Mellon Corp43,144$301K
12DIMENSIONAL FUND ADVISORS LP25,268$176K
13ALLIANCEBERNSTEIN L.P.21,830$154K
14STRS OHIO21,100$147K
15UBS Group AG21,087$147K